Ambitious national targets for getting people on treatment often not reflected in grant performance frameworks, GAC says
In its report to the Board on the third batch of grants it recommended for approval, the Grant Approvals Committee (GAC) said that it was very concerned that national programs have ambitious goals to continue scaling up antiretroviral therapy (ART), with the aim of achieving the 90-90-90 targets or even treating all patients diagnosed with HIV – but that these goals are not necessarily reflected in performance frameworks because of “limitation
Dans ce qui a été salué comme une « percée » et susceptible de « changer la donne », la Fondation Bill et Melinda Gates et deux fabricants de médicaments génériques ont conclu un accord de prix qui entraînera des économies significatives au niveau des coûts des antirétroviraux.
In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.
La demande de financement TB/VIH du Kenya auprès du Fonds mondial se centre sur la prévention du VIH chez les populations clés et la recherche des cas manquants de tuberculose
Le Kenya figure parmi les 35 pays qui ont présenté des demandes de financement au Fonds mondial le 23 mai 2017, date de soumission des candidatures de la deuxième période d’examen.
Kenya’s TB/HIV funding request to the Global Fund zeros in on HIV prevention among key populations and on finding missing TB cases
Kenya was among the 35 countries that submitted funding requests to the Global Fund in Window 2 on 23 May 2017. Kenya’s TB/HIV funding request was for $421.9 million, made up of a $256.4 million allocation request, $138.9 million prioritized above-allocation request (PAAR) and a $26.6 million matching funds request. A $112.0 million malaria funding request was submitted on the same day ($60.1 million within allocation and $51.9 million PAAR).
In October 2016, the Global Fund Board has approved $56.6 million for six grants emanating from concept notes submitted by four countries. Of the $56.6 million, $37.2 million represented new money; the balance was existing funding that has been approved prior to the new funding model (NFM) but was nevertheless included in the NFM allocations to countries. and one regional grant.
Replenishment round-up: U.S. announces pledge of up to $4.3 billion; Kenya raises the bar in Africa; and Sweden restores its 2016 cut
The Global Fund’s Fifth Replenishment Campaign received an important boost from its largest donor, the United States, with the announcement of a pledge of up to $4.3 billion for the 2017-2019 period. This compares to the $4.1 billion that the U.S. contributed for the last replenishment period.
En réponse aux ruptures de stock de médicaments antituberculeux survenus en 2014, et à des risques additionnels identifiés pour les médicaments utilisés contre les trois maladies, le Kenya a mis en place plusieurs mesures pour réduire le risque d’interruption de traitement.
In response to shortages of TB drugs experienced in 2014, and to risks that have been identified of additional shortages for drugs used for all three diseases, Kenya has put in place various measures to reduce the risk of treatment disruptions.
An audit of Global Fund grants to Kenya has found that the management of financial and fiduciary risks, and the management of health services and products risks has been generally effective.
However, the OIG said that there was room for improvement in the management of programmatic and performance risks, as well as governance, oversight and management risks. (In OIG parlance, these were rated “partial plan to become effective.”)